Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 10/20 | 0.34 |
| ▸ | CA9 | Q16790 | 10/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 8/20 | 0.33 |
| ▸ | CA2 | P00918 | 8/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5485344 | 1.00 | NLRP3 (0.37) | NLRP3CA12CA9MAPTCYP3A4 | |
| SCHEMBL1738334 | 1.00 | NLRP3 (0.37) | NLRP3CA12CA9MAPTCYP3A4 | |
| SCHEMBL12157261 | 0.81 | CA12 (0.36) | CA12CA9TSHRCA1CA2 | |
| SCHEMBL12386266 | 0.78 | CYP3A4 (0.40) | CA12CA9MAPTCYP3A4CYP2C19 | |
| SCHEMBL12386229 | 0.78 | CYP3A4 (0.40) | CA12CA9MAPTCYP3A4CYP2C19 | |
| SCHEMBL254386 | 0.78 | CA12 (0.42) | CA12CA9TSHRCA1CA2 | |
| SCHEMBL11548379 | 0.78 | CA12 (0.42) | CA12CA9TSHRCA1CA2 | |
| SCHEMBL11746006 | 0.78 | CA12 (0.42) | CA12CA9TSHRCA1CA2 | |
| SCHEMBL2290500 | 0.78 | CA12 (0.42) | CA12CA9TSHRCA1CA2 | |
| SCHEMBL11548381 | 0.78 | CA12 (0.42) | CA12CA9TSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9861652-B2 | 2′ Fluoronucleosides | EMORY UNIVERSITY (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | EMORY UNIVERSITY | 2016-06-09 | — | — | US | disclosed |
| US-9180138-B2 | 2′-fluoronucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20130157971-A1 | 2'-FLUORONUCLEOSIDES | SCHINAZI RAYMOND F (US) | 2013-06-20 | — | — | US | disclosed |
| US-8168583-B2 | 2-fluoronucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| EP-2392580-A1 | 2'-fluoronucleosides | Emory University (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2390257-A1 | 2'-fluoronucleosides | Emory University (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110256952-A1 | GOLF CLUB, SHAFT REPLACING METHOD AND HEAD REPLACING METHOD | BRIDGESTONE SPORTS CO., LTD. (JP) | 2011-10-20 | — | — | US | disclosed |
| US-20100173863-A1 | 2-Fluoronucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-08 | — | — | US | disclosed |
| US-7662938-B2 | 2′-fluoronucleosides | EMORY UNIVERSITY (US) | 2010-02-16 | — | — | US | disclosed |
| US-20080300398-A1 | 2'-FLUORONUCLEOSIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| US-7307065-B2 | 2′-Fluoronucleosides | EMORY UNIVERSITY (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1754710-A2 | 2'-Fluoroncucleosides | Emory University (US) | 2007-02-21 | — | — | EP | disclosed |
| US-6911424-B2 | 2′-fluoronucleosides | EMORY UNIVERSITY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20040254141-A1 | 2'-Fluoronucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-12-16 | — | — | US | disclosed |
| US-20020198171-A1 | 2'-fluoronucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-26 | — | — | US | disclosed |
| US-6348587-B1 | PURINE OR PYRIMIDINE BASE DERIVATIVES; ANTICANCER, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS; TREATING HIV AND HEPATITIS | EMORY UNIVERSITY | 2002-02-19 | — | — | US | disclosed |
| EP-1058686-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999043691-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198171-A1 | 2'-fluoronucleosides | NSUN2, PNP, FDPS | NLRP3 3746/4885CA12 4425/4885CA9 4616/4885 |
| US-20040254141-A1 | 2'-Fluoronucleosides | NSUN2, PNP, FDPS | NLRP3 3746/4885CA12 4425/4885CA9 4616/4885 |
| US-20100173863-A1 | 2-Fluoronucleosides | PNP, BCL3, NPC1 | NLRP3 4047/4885CA12 3846/4885CA9 4328/4885 |
| US-20080300398-A1 | 2'-FLUORONUCLEOSIDES | METTL3, BCL3, PNP | NLRP3 3445/4885CA12 4320/4885CA9 4283/4885 |
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | PNP, BCL3, NPC1 | NLRP3 4018/4885CA12 3832/4885CA9 4305/4885 |
| US-20130157971-A1 | 2'-FLUORONUCLEOSIDES | PNP, BCL3, FUBP3 | NLRP3 3697/4885CA12 3714/4885CA9 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.